Effects of an Interaction-Based Multi-Care Program on Postpartum Hemorrhage Recovery

Postpartum hemorrhage (PPH) is a severe obstetric complication. While standard medical care addresses the physiological crisis, the psychosocial needs and coping mechanisms of women experiencing PPH may be inadequately addressed by conventional nursing. This prospective, randomized controlled trial aimed to evaluate an interaction standard theory-based multi-care program, integrating King's Theory of Goal Attainment and Satir's model, for women with PPH. Participants (n=110) admitted to Shijiazhuang Obstetrics and Gynecology Hospital from October 2023 to October 2024 were randomly assigned to the study group (n=55) receiving the multi-care program or the control group (n=55) receiving conventional nursing. The multi-care program included collective training for nursing staff, individualized patient data collection, collaborative care plan development, and specific interventions in hemorrhage care, psychological care (empathetic listening, Satir's communication stances, music therapy, guided imagery), cognitive intervention (education on PPH), dietary care, and rehabilitation training. Follow-up occurred at 1 and 2 weeks post-discharge. The study assessed changes in coping styles (SCSQ), psychological distress (HAMD, HAMA), quality of life (WHOQOL-BREF), postpartum recovery indicators (lochia duration, lactation onset, uterine involution, hospital stay), and nursing satisfaction. The study was designed and reported following CONSORT guidelines.

Inclusion criteria

• Delivered in our hospital and received postpartum treatment, with a blood loss >500 mL within 24 hours after delivery;
• Age <40 years;
• Single live birth at full term;
• Stable vital signs;
• No pregnancy-related complications (other than PPH itself post-diagnosis);
• Clear cognitive function and self-awareness;
• Normal hearing and communication ability.

Exclusion criteria

• Cervical laceration (as primary cause of PPH if not manageable by standard protocol and requiring extensive surgical repair beyond typical scope);
• Pre-existing severe cardiovascular diseases;
• Pre-existing severe renal, cardiac, or hepatic insufficiency;
• Known pre-existing coagulation disorders;
• Active systemic infectious diseases;
• Malignant tumors;
• Cellular immune function defects;
• Incomplete data or withdrawal from the study (prior to completion of the 2-week follow-up, though none occurred).